Advice
Following a full submission
Duloxetine is accepted for restricted use within NHS Scotland for the treatment of moderate to severe stress urinary incontinence (SUI). It should be used only as part of an overall management strategy for SUI in addition to pelvic floor muscle training. Patients should be reviewed after 12 weeks of therapy to assess progress and determine whether it is appropriate to continue treatment.
Because of the short duration of treatment in the studies supplied, it is recommended that the manufacturers collect further data on the long-term effects of this pharmacological approach to the management of SUI.
Download detailed advice27KB (PDF)
Medicine details
- Medicine name:
- Duloxetine (Yentreve®)
- SMC ID:
- 119/04
- Indication:
- Stress urinary incontinence
- Pharmaceutical company
- Eli Lilly and Company Ltd
- BNF chapter
- Obstetrics, gynaecology, and urinary-tract disorders
- Submission type
- Full
- Status
- Restricted
- Date advice published
- 11 October 2004